Development and Characterization of Core Shell Nanoparticle for Enhanced Drug Delivery to Treat Solid Tumor: Preparation and In-Vitro Assessment
Mortalities from cancer in the world are projected to continue rising, with an estimated 9 million and 11.4 million people dying from cancer in 2015 and 2030, respectively. Rates are rising as more people live to an old age and as mass lifestyle changes occur in the developing world. With present treating regimen for cancer, dose-limited toxicity is a big reason that reduces the efficacy of cancer treatments. In search for more effective cancer treatments, nanosized drug delivery systems, those are capable of delivering their drug payload selectively to cancer cells such as nanoparticles, solid lipid nanoparticles, liposomes are among the most promising approaches. Core shell nanoparticles are one of the investigated moieties in recent years that are seeking much attention nowadays for biomedical applications including the field of oncology.The present work aims at developing a core shell nanoparticle comprising Poly (D, L –lactide –co –glycolide) (PLGA) core and polyethyleneimine (PEI) shell loaded with anticancer bioactive docetaxel (DTX) for passive targeting of the tumor tissue. It is expected that incorporation of PEI will improve the uptake and subsequent release of the drug in the cytosol due to endosomal escape phenomenon.
Keywords: Solid tumor; nanotechnology; nanoparticle; PLGA
2. Bazak R, Houri M, El Achy S, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Molecular and clinical oncology. 2014; 2(6):904-8.
3. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnology. Springer; 2010. p. 25-37.
4. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proceedings of the Japan Academy, Series B. 2012; 88(3):53-71.
5. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X et al. Lectin-conjugated PEG–PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials. 2006; 27(18):3482-90.
6. Song C, Noh Y-W, Lim YT. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response. International journal of nanomedicine. 2016; 11:3753.
7. Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem. 1978; 90(2):809-15.
8. Gupta M, Chashoo G, Sharma PR, Saxena AK, Gupta PN, Agrawal GP et al. Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery. Molecular pharmaceutics. 2014; 11(3):697-715.
9. Katiyar SS, Kushwah V, Dora CP, Jain S. Novel biosurfactant and lipid core-shell type nanocapsular sustained release system for intravenous application of methotrexate. International journal of pharmaceutics. 2019; 557:86-96.
10. Moosavian SA, Abnous K, Badiee A, Jaafari MR. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids Surf B Biointerfaces. 2016; 139:228-36.
11. Pillai JJ, Thulasidasan AKT, Anto RJ, Devika NC, Ashwanikumar N, Kumar GV. Curcumin entrapped folic acid conjugated PLGA–PEG nanoparticles exhibit enhanced anticancer activity by site specific delivery. RSC Advances. 2015; 5(32):25518-24.
12. Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Tanaka Y et al. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis. Biomaterials. 2018; 154:74-85.
13. Shirakura T, Ray A, Kopelman R. Polyethylenimine incorporation into hydrogel nanomatrices for enhancing nanoparticle-assisted chemotherapy. RSC Advances. 2016; 6(53):48016-24.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).